Drugs / Surabgene Lomparvovec
Surabgene Lomparvovec
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07592273 | Jun 2026 → Jun 2028 expected | diabetic retinopathy | AbbVie | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07007065 | Nov 2025 → Mar 2033 expected | wet macular degeneration | AbbVie | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surabgene Lomparvovec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07007065 ↗ |
| Known as | ABBV-RGX-314 | “Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD).” NCT07007065 ↗ |
| Known as | Sura-vec | “An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered...” NCT07592273 ↗ |
| Known as | Surabgen lomparvovec | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068176 ↗ |
| Route | Other | “subretinal injection” NCT07007065 ↗ |